Compare INBK & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | TNXP |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | 355 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.3M | 198.6M |
| IPO Year | N/A | 2008 |
| Metric | INBK | TNXP |
|---|---|---|
| Price | $25.36 | $14.08 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.25 | N/A |
| AVG Volume (30 Days) | 54.2K | ★ 392.8K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $279.34 | $558.11 |
| Revenue Next Year | $12.97 | $38.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $17.05 | $11.60 |
| 52 Week High | $28.51 | $69.65 |
| Indicator | INBK | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 68.25 | 53.38 |
| Support Level | $21.25 | $13.32 |
| Resistance Level | N/A | $14.52 |
| Average True Range (ATR) | 1.09 | 0.79 |
| MACD | 0.17 | 0.16 |
| Stochastic Oscillator | 90.77 | 63.52 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.